Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer
01 juil. 2021 08h00 HE
|
Achilles Therapeutics PLC
- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator - - CHIRON trial is enrolling up to 40 patients with advanced unresectable or metastatic...
Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
04 juin 2021 09h00 HE
|
Achilles Therapeutics PLC
LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid...
Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
11 mai 2021 07h00 HE
|
Achilles Therapeutics PLC
- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned - - Completed...
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
06 mai 2021 08h00 HE
|
Achilles Therapeutics PLC
LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference
05 mai 2021 08h30 HE
|
Achilles Therapeutics PLC
LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board
03 mai 2021 08h00 HE
|
Achilles Therapeutics PLC
LONDON, United Kingdom, May 03, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid...
Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting
10 avr. 2021 08h30 HE
|
Achilles Therapeutics PLC
LONDON, April 10, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering
06 avr. 2021 16h01 HE
|
Achilles Therapeutics PLC
LONDON, April 06, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...
Achilles Therapeutics Announces Pricing of Initial Public Offering
30 mars 2021 19h00 HE
|
Achilles Therapeutics PLC
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today...